Health Canada
- Status: approved
Combination of low ICS and montelukast (Combination of low ICS and montelukast) regulatory status in Canada.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. Health Canada has authorised it.
Ajou University School of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.